Plexxikon Inc.

Daiichi Sankyo Company, Limited

Genentech, Inc.

Daiichi Sankyo, Inc.

Hamid Rezaei

Prabha N Ibrahim

Gary Conard Visor

Tomoari Kamo

Hiroshi Yamakose

Marika Nespi

Ben Powell

Sanjeev Kothari

Priscilla Mantik

Alexander Mauerer

Rashmin Patel

Piscilla Mantik

Provided are solid dispersions of Compound I having the formula: wherein Compound I is substantially amorphous, methods of manufacturing said solid dispersions, and methods of using said solid dispersions.

Formulations of a compound modulating kinases

Provided are compositions comprising Compound I having the following structure: or a pharmaceutically acceptable salt thereof, and a solubilizing agent; methods of making the same; and methods of using the same.

Forms of 4-(6-(3,5-dimethylisoxazol-4-yl)-1-[(1S)-1-(2-pyridyl)ethyl]pyrrolo[3,2-b]pyridin-3-yl)benzoic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the forms of Compound I.

Solid forms of a compound for modulating kinases

The present disclosure relates generally to rapid-release pharmaceutical dosage unit tablets containing a drug that is an inhibitor of the mitogen-activated protein kinase enzyme, a filler and a disintegrant, and to processes for forming the tablets. More specifically, the present disclosure relates to pharmaceutical dosage unit tablets containing cobimetinib, a least one filler, at least one lubricant and at least one disintegrant, and to methods for preparing the tablets from granules formed by dry granulation.

Immediate-release tablets containing combimetinib and methods of making and using the same

Growing community of inventors

Berkeley, CA, United States of America

Hamid Rezaei